title: Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group.
abstract: OBJECTIVE
  To scrutinize published data from small mono-centric studies and case reports which implicated high response rates and promising survival times for a combination therapy consisting of epifocal dinitrochlorobenzene (DNCB) and dacarbazine (DTIC) for metastasized melanoma. This therapy merges the effects of an allergic contact dermatitis elicited at the site of a cutaneous metastasis, and systemic chemotherapy.
  
  
  METHODS
  We performed a retrospective survey with nine German centers and evaluated 72 patients treated from 1993 to 2005.
  
  
  RESULTS
  The objective response rate in stage III melanoma (n = 39) was 62%. In contrast, only 9% objective responses were observed in 33 stage IV patients. Interestingly, more than half of patients with objective remissions remained progression-free for more than 1 year irrespective of the stage of disease.
  
  
  CONCLUSIONS
  Epifocal DNCB combined with DTIC is effective in patients with regionally metastasized melanoma not amenable to surgery or isolated limb perfusion, whereas in stage IV disease in spite of few durable remissions the addition of DNCB does not improve the therapeutic efficacy of DTIC.
authors.affiliation: Department of Dermatology, University of Würzburg, Josef-Schneider Str. 2, 97080 Würzburg, Germany. terheyden_p@klinik.uni-wuerzburg.de
authors.forename: P
authors.initials: P
authors.lastname: Terheyden
authors.forename: A-K
authors.initials: AK
authors.lastname: Kortüm
authors.forename: H-J
authors.initials: HJ
authors.lastname: Schulze
authors.forename: B
authors.initials: B
authors.lastname: Durani
authors.forename: R
authors.initials: R
authors.lastname: Remling
authors.forename: C
authors.initials: C
authors.lastname: Mauch
authors.forename: V
authors.initials: V
authors.lastname: Junghans
authors.forename: D
authors.initials: D
authors.lastname: Schadendorf
authors.forename: U
authors.initials: U
authors.lastname: Beiteke
authors.forename: M
authors.initials: M
authors.lastname: Jünger
authors.forename: J C
authors.initials: JC
authors.lastname: Becker
authors.forename: E-B
authors.initials: EB
authors.lastname: Bröcker
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003606:Dacarbazine / Q000008:administration & dosage*; D004137:Dinitrochlorobenzene / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D005858:Germany; D006801:Humans; D007509:Irritants / Q000008:administration & dosage*; D008297:Male; D008545:Melanoma; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis
chemical_list: D004137:Dinitrochlorobenzene; D007509:Irritants; D003606:Dacarbazine